Vancouver, Canada, April 17, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0), a pioneering clinical-stage biotechnology company, has made a significant stride in its mission to address critical health challenges through innovative therapies. The company announced today that the United States Patent Office has granted a Notice of Allowance for a patent pertaining to its MEAI (2-Methyl-2-Aminoindane) treatment, specifically designed to target binge behavior.

This newly awarded patent not only enhances the intellectual property protections surrounding Clearminds groundbreaking treatment but also fortifies the companys growing portfolio aimed at novel psychedelic-derived therapeutics. The approval signifies a crucial milestone in the company's ongoing research and development efforts.

Dr. Adi Zuloff-Shani, the CEO of Clearmind Medicine, expressed his enthusiasm regarding the Notice of Allowance, stating, "This Notice of Allowance further strengthens our unique position in the space and growing intellectual property portfolio and reinforces the potential of our robust MEAI program. Securing foundational patent protection is a vital step in supporting our future success and in driving the development of next-generation psychedelic-derived therapeutics with the potential to deliver transformative outcomes for patients." His remarks underscore the company's commitment to pioneering effective treatments that could address significant, often overlooked health issues.

Clearmind Medicine Inc. stands at the forefront of clinical-stage psychedelic pharmaceutical research, focusing on discovering and developing novel therapeutics derived from psychedelics to tackle widespread and under-treated health problems, including, but not limited to, alcohol use disorder. The companys overarching objective is not only to develop these psychedelic-based compounds but also to navigate the complexities of commercializing them as regulated medicines, foods, or dietary supplements.

In terms of intellectual property, Clearmind currently boasts a robust portfolio consisting of nineteen distinct patent families, which includes a total of 31 granted patents. The company is committed to expanding its portfolio by pursuing additional patents whenever warranted and remains open to acquiring further intellectual property to enhance its competitive edge in the market.

For those interested in following Clearmind's progress, shares of the company are actively traded on Nasdaq under the symbol "CMND" as well as on the Frankfurt Stock Exchange with the symbol "CWY0." Investors and the public can access more information about the company through their website at